ReviewInternational journal of molecular sciences2026
The Dynamic Gut Microbiota: Monitoring Alterations During Lung Cancer Progression for Diagnosis and Precision Medicine.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Gut-Lung Microbiome Crosstalk and Pulmonary Disease.Biomolecules · 2026Review
- Case Report: Fecal microbiota transplantation resensitizes advanced non-small cell lung cancer to platinum-based chemotherapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The gut microbiota, the body's richest microbial ecosystem, is essential for maintaining gut function and immune balance. Additionally, microbial-derived metabolites are linked to the onset and progression of various diseases. There is a potential bidirectional gut-lung axis by which the gut and lungs can communicate with each other mediated by microbiota, immune responses, and metabolic products, and thus affect lung cancer occurrence. As the pathological progression of lung cancer advances and treatment methods are optimized, there is a concurrent and continuous alteration in the gut microbiota and its metabolites in lung cancer patients. This review highlights that the composition and structure of the gut microbiota in lung cancer patients undergo dynamic alterations, which are intricately linked to the pathological progression of the disease and the implementation of therapeutic interventions. Longitudinal monitoring of this system may offer unprecedented insights into the early diagnosis, precise treatment, and prognostic evaluation of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.